News and Press Releases
ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies
Pooled results from the BOREAS and NOTUS studies show meaningful clinical benefit with 31% reduction in exacerbations along with lung function improvement Data from these two phase 3 studies supported...
Category: Clinical Trials, Drug Delivery, Pharmaceutical
Posted: September 10, 2024
RYBREVANT▼ (amivantamab) plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy Results from an interim analysis featured in late-breaker...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 8, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Rentschler Biopharma introduces new lentiviral vector manufacturing toolbox for advanced therapies
Expanded service offering client ready at company’s site in Stevenage, UK Offering includes process development and cGMP manufacturing services, as well as complementary in-house analytical and regulatory support for lentiviral...
Category: BioManufacturing, Pharmaceutical Contractors
Posted: September 5, 2024
Expert Speaker Line-Up Revealed for Industry-Leading RBQM Event
CluePoints Supports Launch of RBQMLive 2024 as Premier Event Sponsor 4 September 2024 -- Pennsylvania, US -- CluePoints, the premier sponsor of RBQMLive and provider of Risk-Based Quality Management (RBQM) and...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 4, 2024
European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 27, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
SGS Introduces New Specialized Bioanalytical Testing Services in North America
21 August 2024 -- Geneva, Switzerland -- SGS, the world’s leading testing, inspection and certification company, announces the introduction of new specialized bioanalytical testing services in the North American pharmaceutical...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: August 21, 2024
Touchlight to Supply GMP dbDNA to Support University of Nottingham’s Clinical Study for a Next-Generation Vaccine for Zika Virus
21 August 2024 -- Hampton, UK -- Touchlight, an innovation-driven contract development and manufacturing organization (CDMO) specializing in enzymatic DNA production, is proud to announce the clinical supply of its proprietary...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 21, 2024
New Medable Studio Empowers Sponsors to Launch eCOA Solutions into Clinical Trials with Unparalleled Control and Efficiency
Medable Studio for eCOA now available; two top-10 pharma company early adopters 14 August 2024 -- California, US -- Medable Inc, the leading technology platform for clinical trials, today announced...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: August 14, 2024
COREX Logistics Appoints New CEO to Expand Global Growth
Clinical trial and pharmaceutical logistics specialists COREX Logistics have announced the appointment of Steve Healy as its new CEO of the organisation. Healy, COREX Logistics’ former Vice President of Business...
Category: Clinical Trials, Logistics, Other
Posted: July 30, 2024
Suite 40, The Guinness Enterprise Centre, Taylors Lane, Dublin 8, Ireland
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib1,2,3,4 ...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 26, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive PAH portfolio has the potential to cover all guideline-recommended treatment...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 26, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
AI-enhanced solution will help Eisai accelerate data review and reconciliation by 80% New York – July 25, 2024 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial...
Category: Clinical Trials, Other, Pharmaceutical
Posted: July 25, 2024
Advarra Brings Together Clinical Trial Patient Recruitment Activities to Centralize Visibility and Accelerate Enrolment
New capability provides sponsors and CROs holistic view of sites’ patient recruitment progress 24 July 2024 -- COLUMBIA, MD – – Advarra, the market leader in regulatory review solutions and...
Category: Clinical Trials, Drug Discovery, Other
Posted: July 24, 2024
Touchlight and GSK Sign License Agreement for Use of Enzymatic dbDNA Production Technology for mRNA Manufacturing
Agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing 23 July 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO...
Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: July 23, 2024
ViroCell Biologics signs Master Services Agreement with prominent NCI-designated cancer centre
MSA enables collaboration on full suite of ViroCell’s viral vector manufacturing services to accelerate the cancer centre’s clinical development of novel gene-modified cell therapies Agreement follows ViroCell’s successful GMP manufacture...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: July 22, 2024
